A phase II study of the efficacy and safety of SU011248 [sunitinib] in patients with advanced unresectable neuroendocrine tumor
Phase of Trial: Phase II
Latest Information Update: 10 Mar 2015
At a glance
- Drugs Sunitinib (Primary)
- Indications Neuroendocrine carcinoma
- Focus Therapeutic Use
- 06 Jun 2008 Status changed from in progress to completed.
- 18 Sep 2005 New trial record.